ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury
Summary
USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.
What changed
USPTO issued Patent US12589099B2 on March 31, 2026, granting Alpha Cognition Inc. exclusive rights to ALPHA-1062 pharmaceutical compositions for treating traumatic brain injury. The patent (filed November 25, 2022, Application No. 18549309) contains 27 claims covering the composition, treatment methods using transmucosal/intranasal administration, and a multi-use dispenser device. CPC classifications include A61P 25/00, A61K 31/55, and A61K 9/0043.
Patent grants do not impose compliance obligations on pharmaceutical companies, but organizations developing TBI treatments should conduct freedom-to-operate analyses to assess potential infringement risks. Generic drug manufacturers and biotech firms pursuing similar TBI therapeutics should review this patent's claims to understand the scope of ALPHA-1062 protection before advancing competing programs through clinical development.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Alpha-1062 for treating traumatic brain injury
Grant US12589099B2 Kind: B2 Mar 31, 2026
Assignee
Alpha Cognition Inc.
Inventors
Denis G. Kay
Abstract
A pharmaceutical composition including a compound ALPHA-1062 or salt thereof, or a compound ALPHA-1062 or salt thereof, for use in the treatment of confirmed or suspected traumatic brain injury (TBI) in a subject. In embodiments, the composition is administered transmucosally, such as intranasally, and/or the composition is self-preserving and anti-microbial. Also disclosed is a multi-use dispenser configured for intranasal or transmucosal administration of a pharmaceutical composition including ALPHA-1062 or salt thereof. Also disclosed is a method of treating traumatic brain injury (TBI) in a subject including administering a therapeutically effective amount of a pharmaceutical composition including ALPHA-1062 or salt thereof.
CPC Classifications
A61P 25/00 A61K 31/55 A61K 9/0043
Filing Date
2022-11-25
Application No.
18549309
Claims
27
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.